Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

PMCB Financial Statements and Analysis

NASDAQ : PMCB

PharmaCyte Biotech, Inc.

$1.58
-0.09-538.90%
At Close 4:00 PM
58.16
B-ESG ScoreESG Rating

PMCB FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

PMCB Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateOct 31, 2024Jul 31, 2024Apr 30, 2024Jan 31, 2024Oct 31, 2023
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202420242024
periodQ2Q1Q4Q3Q2
revenue00000
cost of revenue00000
gross profit00000
gross profit ratio00000
research and development expenses97.47K96.016K94.183K126.732K82.033K
general and administrative expenses117.572K783.387K839.553K1.121M1.098M
selling and marketing expenses00232.48K620.777K0
selling general and administrative expenses117.572K783.387K1.072M1.742M1.098M
other expenses891.018K389.484K4.786M-253.00-765.00
operating expenses1.106M1.269M1.166M1.869M1.41M
cost and expenses1.106M1.269M1.166M1.869M1.41M
interest income382.562K547.432K747.098K881.662K894.181K
interest expense00000
depreciation and amortization001.229M1.869K-3.306M
ebitda-1.106M-1.269M1.347M-1.869M-1.41M
ebitda ratio00000
operating income-1.106M-1.269M-1.166M-1.869M-1.41M
operating income ratio00000
total other income expenses net-363.50K24.69M4.513M1.249M4.199M
income before tax-1.47M23.421M1.347M-619.537K2.79M
income before tax ratio00000
income tax expense001.772M-1.869K-894.181K
net income-1.47M23.421M1.347M-619.537K2.79M
net income ratio00000
eps-0.391.900.17-0.0720.32
eps diluted-0.391.900.17-0.0720.32
weighted average shs out7.637M7.866M8.038M8.607M8.765M
weighted average shs out dil7.637M7.866M8.038M8.607M8.765M
Graph

PMCB Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateOct 31, 2024Jul 31, 2024Apr 30, 2024Jan 31, 2024Oct 31, 2023
reported currencyUSDUSDUSDUSDUSD
calendar year20252025202420242024
periodQ2Q1Q4Q3Q2
cash and cash equivalents20.84M32.635M50.18M61.21M73.425M
short term investments00000
cash and short term investments20.84M32.635M50.18M61.21M73.425M
net receivables00000
inventory00000
other current assets493.213K240.227K259.80K297.762K323.189K
total current assets21.333M32.875M50.44M61.508M73.748M
property plant equipment net00000
goodwill00000
intangible assets1.549M1.549M1.549M3.549M3.549M
goodwill and intangible assets1.549M1.549M1.549M3.549M3.549M
long term investments24.855M29.12M7.907M6.294M1.572M
tax assets00000
other non current assets7.361M6.65M7.688K7.687K7.688K
total non current assets33.765M37.319M9.464M9.851M5.129M
other assets0001.000
total assets55.098M70.194M59.904M71.359M78.878M
account payables348.595K553.952K389.369K484.198K126.163K
short term debt00000
tax payables361.529K347.494K340.072K00
deferred revenue00000
other current liabilities4.066M6.572M6.692M7.055M5.113M
total current liabilities4.776M7.473M7.421M7.539M5.24M
long term debt00000
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities6.871M9.68M12.968M14.927M15.573M
total non current liabilities6.871M9.68M12.968M14.927M15.573M
other liabilities00000
capital lease obligations00000
total liabilities11.647M17.153M20.389M22.466M20.813M
preferred stock05.333M11.867M17.519M21.298M
common stock2.167K2.167K2.167K2.167K2.167K
retained earnings-93.673M-92.204M-115.625M-116.972M-116.352M
accumulated other comprehensive income loss-23.267K-23.328K-23.511K-23.073K-24.143K
other total stockholders equity137.145M139.933M143.294M148.368M153.142M
total stockholders equity43.451M53.041M39.515M48.894M58.065M
total equity43.451M53.041M39.515M48.894M58.065M
total liabilities and stockholders equity55.098M70.194M59.904M71.359M78.878M
minority interest00000
total investments24.855M29.12M7.907M6.294M1.572M
total debt00000
net debt-20.84M-32.635M-50.18M-61.21M-73.425M
Graph

PMCB Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateApr 30, 2024Jan 31, 2024Oct 31, 2023Jul 31, 2023Apr 30, 2023
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420242023
periodQ4Q3Q2Q1Q4
deferred income tax00000
stock based compensation674.692B674.693K00-638.072K
change in working capital87.148K135.74K-554.61K630.616K-167.926K
accounts receivables00000
inventory00000
accounts payables-94.828K358.036K-591.967K589.849K-317.654K
other working capital181.976K-222.296K37.357K-589.849K149.728K
other non cash items-1.672M-368.00K-4.22M2.896M643.948K
net cash provided by operating activities-332.958K-177.104K-1.984M342.959K-288.388K
investments in property plant and equipment00000
acquisitions net00000
purchases of investments5.00M-5.00M000
sales maturities of investments00000
other investing activites-5.00T-5.00K000
net cash used for investing activites-5.00T-5.00M-643.249K00
debt repayment-319.919K00-319.919K0
common stock issued33.65T0913.64K35.00M0
common stock repurchased-10.697M-7.039M-164.953K-26.457M-4.307M
dividends paid-22.457T00-319.849K0
other financing activites6.297T-6.638K914.00-1.624M-4.307K
net cash used provided by financing activities-10.697M-7.039M748.687K6.279M-4.307M
effect of forex changes on cash-438.001.07K-1.591K451.00-5.276K
net change in cash-11.03M-12.215M-1.237M6.623M-4.60M
cash at end of period50.18M61.21M73.425M74.663M68.04M
cash at beginning of period61.21M73.425M74.663M68.04M72.64M
operating cashflow-332.958K-177.104K-1.984M342.959K-288.388K
capital expenditure00000
free cash flow-332.958K-177.104K-1.984M342.959K-288.388K
Graph

Frequently Asked Questions

How did PharmaCyte Biotech, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, PMCB generated $0.00 in revenue last quarter, while its costs came in at $0.00.
Last quarter, how much Gross Profit did PharmaCyte Biotech, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. PharmaCyte Biotech, Inc. reported a $0.00 Gross Profit for the quarter ended Apr 30, 2024.
Have PMCB's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. PMCB incurred $1.11M worth of Operating Expenses, while it generated -$1.11M worth of Operating Income.
How much Net Income has PMCB posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from PharmaCyte Biotech, Inc., the company generated -$1.47M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did PharmaCyte Biotech, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to PharmaCyte Biotech, Inc. as of the end of the last quarter was $20.84M.
What are PMCB's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, PMCB had Total Net Receivables of $0.00.
In terms of Total Assets and Current Assets, where did PharmaCyte Biotech, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of PMCB were $21.33M, while the Total Assets stand at $55.10M.
As of the last quarter, how much Total Debt did PharmaCyte Biotech, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of PMCB's debt was $0.00 at the end of the last quarter.
What were PMCB's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, PMCB reported total liabilities of $11.65M.
How much did PMCB's Working Capital change over the last quarter?
Working Capital Change for PMCB was $87.15K over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
PMCB generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. PMCB generated -$332.96K of Cash from Operating Activities during its recently reported quarter.
What was PMCB's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. PMCB reported a -$11.03M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph